• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity

tetano

Editor, Senior Moderator
Cell Rep Med


. 2022 Jan 17;3(2):100510.
doi: 10.1016/j.xcrm.2022.100510. eCollection 2022 Feb 15.
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity


Simone I Richardson[SUP] 1 2 [/SUP], Nelia P Manamela[SUP] 1 2 [/SUP], Boitumelo M Motsoeneng[SUP] 1 2 [/SUP], Haajira Kaldine[SUP] 1 2 [/SUP], Frances Ayres[SUP] 1 2 [/SUP], Zanele Makhado[SUP] 1 2 [/SUP], Mathilda Mennen[SUP] 3 [/SUP], Sango Skelem[SUP] 3 [/SUP], Noleen Williams[SUP] 3 [/SUP], Nancy J Sullivan[SUP] 4 [/SUP], John Misasi[SUP] 4 [/SUP], Glenda G Gray[SUP] 5 [/SUP], Linda-Gail Bekker[SUP] 6 [/SUP], Veronica Ueckermann[SUP] 7 [/SUP], Theresa M Rossouw[SUP] 8 [/SUP], Michael T Boswell[SUP] 7 [/SUP], Ntobeko A B Ntusi[SUP] 9 3 10 11 [/SUP], Wendy A Burgers[SUP] 9 12 11 [/SUP], Penny L Moore[SUP] 1 2 9 13 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. However, while non-neutralizing cytotoxic functions of antibodies are associated with improved disease outcome and vaccine protection, Fc effector function escape from VOCs is poorly defined. Furthermore, whether VOCs trigger Fc functions with altered specificity, as has been reported for neutralization, is unknown. Here, we demonstrate that the Beta VOC partially evades Fc effector activity in individuals infected with the original (D614G) variant. However, not all functions are equivalently affected, suggesting differential targeting by antibodies mediating distinct Fc functions. Furthermore, Beta and Delta infection trigger responses with significantly improved Fc cross-reactivity against global VOCs compared with D614G-infected or Ad26.COV2.S-vaccinated individuals. This suggests that, as for neutralization, the infecting spike sequence affects Fc effector function. These data have important implications for vaccine strategies that incorporate VOCs, suggesting these may induce broader Fc effector responses.

Keywords: Ad26.COV2.S; Beta; Delta; Fc effector function; SARS-CoV-2; variant of concern
 
Back
Top Bottom